Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or des veRsus BMS alone to EliminAte Restenosis (CEREA-DES)

European Heart Journal

Volumn 34, Issue 23, 2013, Pages 1740-1748

  Ribichini, Flavio ^a,b   Tomai, Fabrizio ^c   Pesarini, Gabriele ^a   Zivelonghi, Carlo ^a   Rognoni, Andrea ^d   De Luca, Giuseppe ^d   Boccuzzi, Giacomo ^e   Presbitero, Patrizia ^f   Ferrero, Valeria ^a   Ghini, Anna S ^c   Marino, Paolo ^d   Vassanelli, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c EUROPEAN HOSPITAL   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Coronary artery disease; Long term follow up; Prednisone; Randomized clinical trial; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PREDNISONE; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EVENT FREE SURVIVAL; EXERCISE TEST; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STENT THROMBOSIS; SUDDEN DEATH; TREATMENT DURATION;

CORONARY ARTERY DISEASE; LONG-TERM FOLLOW-UP; PREDNISONE; RANDOMIZED CLINICAL TRIAL; STENT;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; CORONARY RESTENOSIS; CORTISONE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PREDNISONE; SIROLIMUS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84879078992     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht079     Document Type: Article

References (29)

1. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C. A multicenter, randomised study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versusBMS alone to eliminate restenosis (CEREA-DES)-study design and rationale. J Cardiovasc Med 2009;10:192-199.
2. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffrè PA, Romeo F, Crea F. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-1942.
3. Ribichini F, Tomai F, Ferrero V, Versaci F, Boccuzzi G, Proietti I, Prati F, Crea F, Vassanelli C. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD Study. Eurointervention 2005;2:173-180.
4. Ferrero V, Tomai F, Versaci F, Feola M, Proietti I, Rognoni A, Ghini AS, Gaspardone A, Vacca G, De Luca L, Vassanelli C, Ribichini F. Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated c-reactive protein levels. Eurointervention 2009;5:250-254.
5. Farb A, Sangiorgi G, Carter AJ,Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99: 44-52.
6. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980.
7. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Abukaresh R, Aurigemma C, De Luca L, Zavalloni D, Soregaroli D, Marino P, Garbo R, Zanolla L, Vassanelli C. CEREA-DES investigators. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomised trial. Am J Med 2011;124:434-443.
8. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids. New mechanisms for old drugs. N Engl J Med 2005;353:1711-1723.
9. Ferrero V, Ribichini F, Pesarini G, Brunelleschi S, Vassanelli C. Therapeutic potential of glucocorticoids in the prevention of restenosis after coronary angioplasty. Drugs 2007;67:1243-1255.
10. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-146.
11. Silber S, Windecker S, Vranckx P, Serruys PW. RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-1247.
12. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-1322.
13. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008;359:2195-2207.
14. Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS. COURAGE Trial Investigators. Impact of optimal medical therapy with or without percutaneous coronary intervention on longterm cardiovascular endpoints in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol 2009;104:1-4.
15. Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Kihara T, Tanaka N, Nakaya K, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI. Eur J Cardiovasc Prev Rehabil 2009;16:222-228.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115: 2344-2351.
17. Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stent: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trail. Circulation 2011;123:2819-2828.
18. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K. j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-591.
19. Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, Kastrati A, Schömig A, Mehilli J. OSIRIS Trial Investigators. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv 2009;2:1142-1148.
20. Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW. ORAR III Investigators. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention 2009;5:255-264.
21. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G. ORAR II Investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomised Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006;47:1522-1529.
22. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-1392.
23. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhö fer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A. OSIRIS Investigators. Randomised, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110:790-795.
24. Uchimura N, Perera GB, Fujitani RM, Tobis JM, Ishimaru S, Wilson SE, Gordon IL. Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin. Ann Vasc Surg 2004;18:172-177.
25. Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD, Vassanelli C, Virmani R. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007;50: 176-185.
26. Pesarini G, Amoroso A, Ferrero V, Bardelli C, Fresu LG, Perobelli L, Scappini P, De Luca G, Brunelleschi S, Vassanelli C, Ribichini F. Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans. Atherosclerosis 2010;211:242-248.
27. Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 2011;86:297-303.
28. Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev 2011;5(10):CD000407.
29. Rizzari MD, Suszynski TM, Gillingham KJ, Dunn TB, Ibrahim HN, Payne WD, Chinnakotla S, Finger EB, Sutherland DE, Kandaswamy R, Najarian JS, Pruett TL, Kukla A, Spong R, Matas AJ. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol 2012;7:494-503.